Tenaya Therapeutics Reports Positive Gene Therapy Data, Alnylam Partnership, and Regulatory Path Forward
TNYA has more than doubled off its 52-week low of $0.36.
Summary
Tenaya Therapeutics announced its fourth quarter and full year 2025 financial results and provided a comprehensive business update. The company reported promising data from its MyPEAK-1 Phase 1b/2 clinical trial for TN-201 (HCM gene therapy), including improved patient outcomes and resumed enrollment. It also highlighted early data for TN-401 (ARVC gene therapy) and plans to pursue regulatory alignment for pivotal trial plans for both programs in 2026. Additionally, Tenaya announced a new multi-target research collaboration with Alnylam Pharmaceuticals. While the extended cash runway into the second half of 2027 and preclinical data for TN-301 were previously reported, these new clinical advancements and the Alnylam partnership represent significant positive developments for the company's pipeline and future prospects. Investors will be watching for the upcoming data readouts and regulatory updates throughout 2026.
At the time of this announcement, TNYA was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.9M. The 52-week trading range was $0.36 to $2.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.